Fuse raises $25M to disrupt aging loan origination systems used by US credit unions
17 March 2026 at 01:43
The startup also announced a $5 million "rescue fund" to help credit unions ditch legacy software for its AI-native platform.
Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9
In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.